FY2026 Earnings Forecast for MIST Issued By HC Wainwright

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Equities research analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a note issued to investors on Monday, December 15th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of ($0.70) per share for the year, up from their previous forecast of ($0.71). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Milestone Pharmaceuticals’ current full-year earnings is ($0.62) per share. HC Wainwright also issued estimates for Milestone Pharmaceuticals’ FY2027 earnings at ($0.61) EPS, FY2028 earnings at $0.53 EPS and FY2029 earnings at $1.03 EPS.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.05.

Several other analysts have also issued reports on the stock. TD Cowen upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.00 target price for the company in a research report on Monday. Wells Fargo & Company boosted their price objective on shares of Milestone Pharmaceuticals from $4.00 to $8.00 and gave the company an “overweight” rating in a research report on Tuesday. Weiss Ratings restated a “sell (d-)” rating on shares of Milestone Pharmaceuticals in a research note on Monday. Wall Street Zen downgraded Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Cowen upgraded Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Milestone Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Milestone Pharmaceuticals Price Performance

NASDAQ MIST opened at $2.20 on Wednesday. The company has a 50-day moving average price of $2.19 and a 200-day moving average price of $1.92. Milestone Pharmaceuticals has a 52 week low of $0.63 and a 52 week high of $3.06. The company has a quick ratio of 8.24, a current ratio of 8.24 and a debt-to-equity ratio of 2.74. The firm has a market capitalization of $187.37 million, a P/E ratio of -2.68 and a beta of 0.41.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of MIST. Propel Bio Management LLC bought a new stake in Milestone Pharmaceuticals during the first quarter valued at about $1,161,000. Walleye Capital LLC purchased a new stake in shares of Milestone Pharmaceuticals during the first quarter worth about $74,000. Simplify Asset Management Inc. raised its stake in Milestone Pharmaceuticals by 16.5% during the 2nd quarter. Simplify Asset Management Inc. now owns 990,000 shares of the company’s stock valued at $1,921,000 after purchasing an additional 140,000 shares during the period. Valeo Financial Advisors LLC lifted its holdings in Milestone Pharmaceuticals by 553.5% in the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock worth $254,000 after purchasing an additional 110,699 shares in the last quarter. Finally, Bay Rivers Group purchased a new position in Milestone Pharmaceuticals in the 2nd quarter worth approximately $28,000. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.